Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

TENX

TENAX THERAPEUTICS, INC.

Pharmaceutical Preparations · SIC 2834CIK 34956Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$0.0M
Net Income FY2025
$(53.0M)
EPS (Basic, as reported)
$-1.34
Net Margin FY2025
—
ROE FY2025
-54.2%
Total Equity
$97.0M
Shares Out
37M
Business description

TENAX THERAPEUTICS, INC. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2011–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 0 → 0
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023⚑FY2024⚑FY2025
Revenue0———————00
Cost of revenue0—————————
Gross profit0—————————
Research & development(13)(4)(1)(3)(5)(25)(5)(3)(13)(33)
Selling, general & administrative(6)(6)(6)(5)(5)(8)————
General & administrative—————(8)(6)(5)(7)(24)
Total operating expenses(53)(9)(7)(9)(10)(33)(11)(8)(19)(56)
Operating income(53)(9)(7)(9)(10)33(11)8(19)(56)
Interest expense0——0000000
Other income (expense), net10000—0(1)00
Income tax expense(8)000000000
Net income(44)(9)(14)(8)(10)(32)(11)8(18)(53)
EPS — basic———————($31.04)($1.15)($1.34)
EPS — diluted———————($31.04)($1.15)($1.34)
Shares outstanding — basic (M)———————01539
Shares outstanding — diluted (M)———————01539

Showing the latest 10 of 15 fiscal years.

  • ⚑ Weighted-average shares changed ÷1.85 between FY2015 and FY2024 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ×2.60 between FY2024 and FY2025 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.